Main changes included: • Data collection after the follow-up period was extended to include not only subject’s survival status but also subsequent anticancer treatment data and response (if available). • Mandatory contraception was extended from 3 months to 12 months after the last study drug administration. • As the primary endpoint is overall survival, survival data had to be collected within the remit of the protocol. Therefore, follow-up after week 30 was until death for each subject.

Main changes included: • A syphilis test was added at screening and the hepatitis A test was removed to align with the information in the IMPD. • It was clarified that subjects had to undergo of DTH skin test after 3 DC treatments to determine if DC treatment resulted in a detectable immune response.

Main changes included: • Additional immunomonitoring and biomarker samples were added at leukapheresis. Further, it was specified that leukapheresis could be repeated if MesoPher production failed or did not meet release specifications. Serology had to be within 4 weeks of leukapheresis procedure. • Modified RECIST criteria were removed as diagnostic criteria.

Main changes included: • It was clarified that concurrent bevacizumab during chemotherapy and during the first 6 weeks after completion of chemotherapy was allowed but subjects who received bevacizumab were only eligible if they stopped bevacizumab due to non-tolerance before or by the end of the chemotherapy period. Subjects who benefitted from bevacizumab use could continue treatment with bevacizumab and were consequently not eligible for the study.

Main changes included: • Circumstances in which delayed leukapheresis could be permitted were defined. • Procedures for manufactured product out of date were defined. Procedures for cases in which repeat leukapheresis was not possible were defined.

Main changes included: • It was clarified that the intention is that subjects would continue to be followed-up for survival, tumour response and possibly subsequent treatments after the end of study (12 months after randomization of the last subject into the study, when at least 101 events had occurred). • The COVID-19 pandemic had a serious effect on the recruitment rate in the study. To reach the originally planned 230 subjects would take unrealistically long. Hence the number of patients to be recruited was reduced to at least 164. • In view of the reduction in sample size, the interim analysis with the aim to re-estimate the sample size, was no longer relevant and was thus removed. • As a consequence of travel restrictions in relation to the COVID-19 pandemic, 4 instead of 6 study centers were involved in the study (centers in the UK and Italy were closed without having recruited subjects). • A number of additional sensitivity analysis were added.